NEW YORK, NY--(Marketwired - November 28, 2016) - Accurexa, Inc. (OTCQB: ACXA), a small-cap biotech focused on chemotherapy and immunology, is an up-and-coming leader in the neurological therapy space. Currently, Accurexa is working on the targeted delivery of such therapies, specifically the direct delivery of chemotherapeutics that effectively and safely cross the blood-brain barrier, www.accurexa.com.
According to Allied Market Research, the market opportunity for oncology treatments is forecast to reach $111.9 billion by 2020, achieving a compound annual growth rate of 7.1 percent. In 2015, the global cancer drugs market reached $78.24 billion, largely driven by increased demand for biological and targeted drug therapies for various cancers.
Leading the market are immunotherapy drugs, which offer a desirable risk-reward profile. The past few years have seen a tremendous boost in sentiment toward targeted cancer therapies due to their ability to protect healthy cells from toxic side effects common in other treatments.
The medical device market has many up and coming investment opportunities targeting a wide variety of health conditions and diseases. Consider Integra Lifesciences Holdings Corp. (NASDAQ: IART), a company which has a range of products targeting neurosurgery and implants, helping doctors deliver the best surgery by providing the right tools for each operation. With a market cap of $2.93 billion and 26 percent growth on share price, this company offers strong growth potential for investors.
Cardiovascular Systems (CSII) has developed heart implants and devices. With heart disease the leading cause of death worldwide, the potential market is tremendous. In 2012 alone, 17.5 million people died due to cardiovascular events. CSII has a range of products all designed to target coronary artery disease. By offering catheter delivery of stents, this company helps patients get rapid treatment with minimal recovery times. A market cap of $797.13 million gives investors plenty to look at when considering this company. CSII has realized gains of 65 percent, even with the uncertainty currently plaguing the market.
ACXA, however, is developing multiple therapies in conjunction with several biotech companies and universities. ACX-31, for example, is a local chemotherapy wafer designed to treat brain cancer. It is being developed with Johns Hopkins University and DelMar Pharmaceuticals (NASDAQ: DMPI).
Further, Accurexa is collaborating with StemImmune in the development of stem cell-mediated immunotherapy for the treatment of cancer and with University of California San Francisco (UCSF) in the treatment of Parkinson's disease through ACXA's "BranchPoint" delivery device. This device delivers therapeutics through a delivery catheter by way of a single brain penetration to treat neurodegenerative diseases and more.
ACXA stock is currently trading for 0.55 cents and is down 1.25 percent year to date. However, a solid market cap of $4.45 million makes this company a startup opportunity, given that it dramatically outperforms the market. For comparison, the Nasdaq Biotechnology Index (IBB) is down 24 percent in 2016.
This article was funded and distributed by FMW Media Works Corp. which holds over 250,000 shares between itself and close affiliates. All shares will be sold as soon as possible. In addition, FMW Media Works Corp will be producing and airing nationwide a 30 minute special featuring Accurexa and its stem cell partners on "New To The Street" T.V.
About FMW Media Works Corp. ("New To The Street")
FMW Media Works Corp. is a leading provider of business profiles and special corporate programming. FMW Media Works produces "New To The Street" which paves the way to the latest financial issues, offering a blend of business and financial services news reporting and in-depth interviews relating to new products, economic analysis, and public company profiles. "New To The Street" airs as paid TV programming, and airs in the United States reaching potentially 100 million homes, in Canada reaching potentially more than 5.3 million homes and viewed on other select International stations. Visit www.NewToTheStreet.com.
Forward-Looking Statements Disclaimer:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that is contained in the Edgar Archives of the Securities and Exchange Commission at www.sec.gov.